These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31595800)

  • 1. Tacrolimus in adult hematopoietic stem cell transplantation.
    Gao Y; Ma J
    Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):803-811. PubMed ID: 31595800
    [No Abstract]   [Full Text] [Related]  

  • 2. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation.
    Gao L; Liu J; Zhang Y; Chen X; Gao L; Zhang C; Liu Y; Kong P; Zhong J; Sun A; Du X; Su Y; Li H; Liu H; Peng X; Zhang X
    Leuk Res; 2017 Jun; 57():27-36. PubMed ID: 28273549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases.
    Nasu R; Nannya Y; Shinohara A; Ichikawa M; Kurokawa M
    Ann Hematol; 2014 Jul; 93(7):1215-23. PubMed ID: 24590535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic comparison of cyclosporin A and tacrolimus in graft-versus-host disease prophylaxis.
    Moiseev IS; Burmina EA; Muslimov AR; Pirogova OV; Bondarenko SN; Darskaya EI; Tarakanova YA; Senina NG; Afanasyev BV
    Ann Hematol; 2017 Jun; 96(6):935-942. PubMed ID: 28343273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
    Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
    Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Usefulness of a slow-release tacrolimus for a patient with tacrolimus-induced renal injury after hemopoietic stem cell transplantation].
    Hosonuma R; Fujiwara S; Sasazaki M; Hirata Y; Yamamoto C; Uesawa M; Oh I; Matsuyama T; Mori M; Ozawa K; Muroi K
    Rinsho Ketsueki; 2012 Apr; 53(4):469-71. PubMed ID: 22687983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Khaled SK; Palmer JM; Herzog J; Stiller T; Tsai NC; Senitzer D; Liu X; Thomas SH; Shayani S; Weitzel J; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):268-276. PubMed ID: 26325438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of early post-hematopoietic stem cell transplant tacrolimus concentration on transplant outcomes in pediatric recipients: One facility's ten-year experience of immunosuppression with tacrolimus.
    Braidotti S; Curci D; Maestro A; Zanon D; Maximova N; Di Paolo A
    Int Immunopharmacol; 2024 Sep; 138():112636. PubMed ID: 38991629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics for once-daily modified release formulation of tacrolimus hydrate in unrelated hematopoietic stem cell transplantation.
    Yano S; Mori S; Saito T; Yokoyama H; Machishima T; Shimada T; Yahagi Y; Sugiyama K; Ogasawara Y; Takahara S; Kasama K; Katsube A; Kamiyama Y; Suzuki K; Inui Y; Usui N; Aiba K; Yamashita T
    Ann Hematol; 2015 Mar; 94(3):491-6. PubMed ID: 25325985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.
    Pidala J; Walton K; Elmariah H; Kim J; Mishra A; Bejanyan N; Nishihori T; Khimani F; Perez L; Faramand RG; Davila ML; Nieder ML; Sagatys EM; Holtan SG; Lawrence NJ; Lawrence HR; Blazar BR; Anasetti C; Sebti SM; Betts BC
    Clin Cancer Res; 2021 May; 27(10):2712-2722. PubMed ID: 33753457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
    Zhu J; Campagne O; Torrice CD; Flynn G; Miller JA; Patel T; Suzuki O; Ptachcinski JR; Armistead PM; Wiltshire T; Mager DE; Weiner DL; Crona DJ
    Clin Transl Sci; 2021 May; 14(3):908-918. PubMed ID: 33502111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives.
    Degraeve AL; Moudio S; Haufroid V; Chaib Eddour D; Mourad M; Bindels LB; Elens L
    Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):769-782. PubMed ID: 32721175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT.
    Oshima K; Sato M; Terasako K; Kimura S; Okuda S; Kako S; Kanda Y
    Bone Marrow Transplant; 2010 Apr; 45(4):781-2. PubMed ID: 19701249
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
    Mori T; Kato J; Shimizu T; Aisa Y; Nakazato T; Yamane A; Ono Y; Kunimoto H; Okamoto S
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):229-34. PubMed ID: 21708109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation.
    David-Neto E; Romano P; Kamada Triboni AH; Ramos F; Agena F; Almeida Rezende Ebner P; Altona M; Galante NZ; Brambate Carvalhinho Lemos F
    Transplantation; 2017 Jun; 101(6):1365-1372. PubMed ID: 27482958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.
    Tang JT; Andrews LM; van Gelder T; Shi YY; van Schaik RH; Wang LL; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):555-65. PubMed ID: 27010623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Medication Level Variability Index (MLVI) as a potential predictive biomarker of graft-versus-host disease in pediatric hematopoietic stem cell transplant patients.
    Skeens MA; Dietrich MS; Ryan-Wenger N; Gilmer MJ; Mulvaney SA; Akard TF
    Pediatr Transplant; 2019 Aug; 23(5):e13451. PubMed ID: 31066981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation.
    Jacobson P; Uberti J; Davis W; Ratanatharathorn V
    Bone Marrow Transplant; 1998 Aug; 22(3):217-25. PubMed ID: 9720734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.